Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Accession Requirements for ICH Assembly Hammered Out at Fukuoka Confab
The International Conference on Harmonization (ICH) agreed on the eligibility requirements for members of a newly set up ICH assembly at its meeting in Fukuoka, southwestern Japan. At the meeting, held for six days through June 11, the ICH agreed…
To read the full story
Related Article
- Q&A Document on GMP for APIs Reaches Step 4: ICH Meeting in Fukuoka
July 13, 2015
- ICH Likely to OK Brazil, China as Assembly Members at Fukuoka Confab
May 26, 2015
- MHLW Releases Discussion Outline of ICH Lisbon Meeting
December 18, 2014
- Outline of New Global Clinical Trial Guidelines Agreed On at ICH Confab in Lisbon
December 12, 2014
- ICH Makes Progress Toward Greater Inclusivity, Agrees to Establish Assembly at November Meeting in Lisbon
December 4, 2014
- Can a More-Open ICH Maintain “Tri-Polar” Leadership? - Key Focus at Lisbon Meeting
November 5, 2014
- ICH M7 Guideline Reaches Step 4; MHLW to Issue Notification
July 22, 2014
- ICH to Facilitate Participation of Regulatory Authorities from Non-ICH Regions in Future Activities
July 30, 2013
- eCTD Progresses to Step 4 at ICH in Brussels
July 18, 2013
- What Next for a “Mature” ICH? What More Can Be Done Beyond Regulatory Harmonization?
January 22, 2013
REGULATORY
- 4 Drug Makers Seek Govt Aid to Upgrade Aging Plants: LDP Hearing
August 24, 2026
- 679 Safety Reports Logged for Regenerative Medical Products in 2H FY2025
August 21, 2026
- Japan Panel to Discuss Approval of 6 NMEs, Leqembi SC on Aug. 26
August 20, 2026
- DPP Lawmaker Calls for Inflation Relief in 2027 Off-Year Drug Price Revision
August 19, 2026
- CEA Review Group Wraps Up Technical Debate, Urges More Company Access
August 19, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…